Dimitrios Makrakis
Overview
Explore the profile of Dimitrios Makrakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Talukder R, Bakaloudi D, Makrakis D, Diamantopoulos L, Enright T, Leary J, et al.
Clin Genitourin Cancer
. 2025 Jan;
23(1):102284.
PMID: 39798390
Background: FGFR2/3, MTAP and ERBB2 genomic alterations have treatment targets in advanced urothelial carcinoma (aUC). These alterations may affect tumor microenvironment and outcomes with immune checkpoint inhibitors (ICIs) in aUC....
2.
Makrakis D, Msaouel P, Karam J, Esagian S
Eur Urol Focus
. 2024 Dec;
PMID: 39667984
Background And Objective: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors (ICIs) is controversial. We aimed to investigate the...
3.
Esagian S, Karam J, Msaouel P, Makrakis D
Eur Urol Focus
. 2024 Sep;
PMID: 39289076
Background And Objective: Despite its well-established role in metastatic renal cell carcinoma (mRCC), the optimal timing of cytoreductive nephrectomy (CN) is unclear. The aim of this systematic review is to...
4.
Bakaloudi D, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary J, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102198.
PMID: 39241315
Background: Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) are associated with immune checkpoint inhibitor (ICI) efficacy. We examined the association between TMB and MSI status with survival in patients...
5.
Makrakis D, Dambri O, Hafid A
Sensors (Basel)
. 2024 Apr;
24(8).
PMID: 38676201
This paper presents an enhanced version of our previously developed bio-optical transceiver, presenting a significant advancement in nanosensor technology. Using self-assembled polymers, this nanodevice is capable of electron detection while...
6.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, et al.
PLoS One
. 2023 Nov;
18(11):e0294382.
PMID: 37943834
[This corrects the article DOI: 10.1371/journal.pone.0252537.].
7.
Makrakis D, Rounis K, Tsigkas A, Georgiou A, Galanakis N, Tsakonas G, et al.
PLoS One
. 2023 Nov;
18(11):e0294384.
PMID: 37943779
[This corrects the article DOI: 10.1371/journal.pone.0277708.].
8.
Bakaloudi D, Talukder R, Lin G, Makrakis D, Diamantopoulos L, Tripathi N, et al.
Clin Genitourin Cancer
. 2023 Jul;
21(5):584-593.
PMID: 37414620
Background: Platinum-based chemotherapy (PBC) followed by avelumab switch maintenance in nonprogressors is standard first line (1L) treatment for advanced urothelial carcinoma (aUC). We describe clinical features and outcomes in a...
9.
Storm E, Makrakis D, Lin G, Talukder R, Bakaloudi D, Shah E, et al.
Target Oncol
. 2023 Jun;
18(4):601-610.
PMID: 37358780
Background: Immune-related hepatitis (irH) is a serious immune-related adverse event (IRAE) that may result in morbidity, immune checkpoint inhibitor (ICI) therapy interruption and, rarely, mortality. The impact of underlying liver...
10.
Azarnoush A, Dambri O, Karatop E, Makrakis D, Cherkaoui S
IEEE Trans Biomed Eng
. 2023 Apr;
70(9):2616-2623.
PMID: 37030752
Providing sufficient energy for autonomous systems at the nanoscale is one of the major challenges of the Internet of Nano Things (IoNT). Existing battery technologies and conventional integrated circuits cannot...